Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8219)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jan 15, 2021 (publication date) through Nov 5, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Fu ZD, Cai XL, Yang WJ, Zhao MM, Li R, Li YF. Novel glucose-lowering drugs for non-alcoholic fatty liver disease. World J Diabetes 2021; 12(1): 84-97 [PMID: 33520110 DOI: 10.4239/wjd.v12.i1.84] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v12/i1/84.htm |
| Number | Citing Articles |
| 1 |
Sora Kwon, Reshani Jeyaratnam, Kyoung-Han Kim. Targeting ketone body metabolism to treat fatty liver disease. Journal of Pharmacy & Pharmaceutical Sciences 2024; 27 doi: 10.3389/jpps.2024.13375
|
| 2 |
Lei Sun, Chaohua Deng, Yunpeng Gu, Yining He, Luping Yang, Junping Shi. Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. Clinics and Research in Hepatology and Gastroenterology 2022; 46(4): 101876 doi: 10.1016/j.clinre.2022.101876
|
| 3 |
Kyuyeon Cho, Seoyeon Park, Ai Koyanagi, Louis Jacob, Dong Keon Yon, Seung Won Lee, Min Seo Kim, Seung Up Kim, Beom Kyung Kim, Jae Il Shin, Lee Smith. The effect of pharmacological treatment and lifestyle modification in patients with nonalcoholic fatty liver disease: An umbrella review of meta‐analyses of randomized controlled trials. Obesity Reviews 2022; 23(9) doi: 10.1111/obr.13464
|
| 4 |
André J. Scheen. Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update. Expert Opinion on Drug Metabolism & Toxicology 2023; 19(8): 543 doi: 10.1080/17425255.2023.2252333
|
| 5 |
Mitsuhiro Shikamura, Atsushi Takayama, Masato Takeuchi, Koji Kawakami. Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic dysfunction‐associated steatotic liver disease: A retrospective nationwide claims database study in Japan. Diabetes, Obesity and Metabolism 2024; 26(8): 3099 doi: 10.1111/dom.15632
|
| 6 |
Wen-Ling Lee, Peng-Hui Wang, Szu-Ting Yang, Chia-Hao Liu, Wen-Hsun Chang, Fa-Kung Lee. To Do One and To Get More: Part II. Diabetes and metabolic dysfunction-associated fatty liver diseases. Journal of the Chinese Medical Association 2022; doi: 10.1097/JCMA.0000000000000831
|
| 7 |
Ke He, Jingxin Li, Wang Xi, Jun Ge, Jingna Sun, Zeng Jing. Dapagliflozin for nonalcoholic fatty liver disease: A systematic review and meta-analysis. Diabetes Research and Clinical Practice 2022; 185: 109791 doi: 10.1016/j.diabres.2022.109791
|
| 8 |
Ioannis Ilias, Costas Thomopoulos. Non-alcoholic fatty liver disease, diabetes medications and blood pressure. World Journal of Diabetes 2021; 12(10): 1809-1811 doi: 10.4239/wjd.v12.i10.1809
|
| 9 |
Andrea del Carmen Maldonado-Rojas, Julia María Zuarth-Vázquez, Misael Uribe, Varenka J Barbero-Becerra. Insulin resistance and Metabolic dysfunction-associated steatotic liver disease (MASLD): Pathways of action of hypoglycemic agents. Annals of Hepatology 2024; 29(2): 101182 doi: 10.1016/j.aohep.2023.101182
|
| 10 |
Manqiu Mo, Zichun Huang, Yuzhen Liang, Yunhua Liao, Ning Xia. The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: An updated meta-analysis. Digestive and Liver Disease 2022; 54(4): 461 doi: 10.1016/j.dld.2021.08.017
|
| 11 |
André J. Scheen. Comparative effects between old and new antidiabetic agents on metabolic- associated fatty liver disease (MAFLD). Diabetes Epidemiology and Management 2023; 11: 100145 doi: 10.1016/j.deman.2023.100145
|
| 12 |
Yunpeng Gu, Lei Sun, Yining He, Luping Yang, Chaohua Deng, Run Zhou, Tingting Kong, Wei Zhang, Yutong Chen, Jie Li, Junping Shi. Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials. Expert Review of Gastroenterology & Hepatology 2023; 17(3): 273 doi: 10.1080/17474124.2023.2172397
|
| 13 |
Yousaf Zafar, Ahmed Mustafa Rashid, Ahmed Kamal Siddiqi, Aayat Ellahi, Aymen Ahmed, Hassan ul Hussain, Furqan Ahmed, Ritesh G. Menezes, Tariq Jamal Siddiqi, Muhammad Talha Maniya. Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clinics and Research in Hepatology and Gastroenterology 2022; 46(7): 101970 doi: 10.1016/j.clinre.2022.101970
|
| 14 |
Abdulrahman I. Alfayez, Jawaher M. Alfallaj, Mugahid A. Mobark, Abdullah A. Alalwan, Osamah M. Alfayez. An Update on the Effect Of Sodium Glucose Cotransporter 2 Inhibitors on
Non-Alcoholic Fatty Liver Disease: A Systematic Review of Clinical Trials. Current Diabetes Reviews 2024; 20(2) doi: 10.2174/1573399820666230525150437
|
| 15 |
Richeek Pradhan, Hui Yin, Oriana Yu, Laurent Azoulay. Glucagon-Like Peptide 1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes. Diabetes Care 2022; 45(4): 819 doi: 10.2337/dc21-1953
|
| 16 |
Yunpeng Gu, Lei Sun, Wei Zhang, Tingting Kong, Run Zhou, Yining He, Chaohua Deng, Luping Yang, Jianing Kong, Yutong Chen, Junping Shi, Yanli Hu. Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1102792
|